AstraZeneca results: 9M and Q3 2026
AstraZeneca reported 9M 2026 revenue of $46.88bn, up 7% YoY, with Q3 2026 revenue at $16.21bn, also up 7%. Core EPS rose 14% YoY to $8.00. The company highlighted 12 positive Phase III readouts and approvals for four new medicines. AstraZeneca reconfirmed FY 2026 guidance and announced a $2bn investment in Summit Therapeutics. The company also launched a $2bn restructuring program for sustainable growth.
How this was made
The 30-second read
Why it matters
The earnings beat and strategic investments signal continued growth momentum, likely supporting the stock price in the short term.
Market read
First‑report earnings with solid growth and guidance reaffirmation provide a clear trading catalyst for AZN.
What to watch
Potential headwinds from Farxiga and Brilinta loss of exclusivity and China procurement could temper long‑term growth.
Background
AstraZeneca's 2026 interim financial release includes detailed revenue, EPS, and pipeline updates, plus a $2 bn equity investment in Summit Therapeutics.
Ticker impact
AstraZeneca released its 9M and Q3 2026 results, showing total revenue up 7% YoY and core EPS up 14% with reaffirmed FY 2026 guidance.
likely modest upside as investors price in revenue growth and stable guidance
Revenue and EPS growth exceed prior expectations and the company reaffirmed guidance, reducing uncertainty.
Market effects
Strengthens the pharmaceutical sector outlook, especially oncology and rare‑disease pipelines.
Positive for European and US markets where AZN ADR trades.
Adds confidence to global biotech and pharma investors.
Counterpoint
If the market had already priced in strong growth, the reaffirmed guidance may be seen as a neutral update, limiting upside.
Key entities
- CompanyAstraZeneca
Global pharmaceutical company reporting FY 2026 interim results.
- CompanySummit Therapeutics
Biotech firm in which AZN took a 12% equity stake.
